CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.
[CytoDyn, Inc.]
7992332
nan
items
1
apa
0
default
asc
1
164540
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/